现代中西医结合杂志
現代中西醫結閤雜誌
현대중서의결합잡지
Modern Journal of Integrated Traditional Chinese and Western Medicine
2015年
32期
3542-3545
,共4页
何阳%赵保成%刘洪强%王赛博%郑晓辉%曹军
何暘%趙保成%劉洪彊%王賽博%鄭曉輝%曹軍
하양%조보성%류홍강%왕새박%정효휘%조군
塞来昔布%吉西他滨%动脉灌注化疗%肺癌
塞來昔佈%吉西他濱%動脈灌註化療%肺癌
새래석포%길서타빈%동맥관주화료%폐암
celecoxib%gemcitabine%arterial chemotherapy%lung cancer
目的:研究塞来昔布联合吉西他滨经动脉灌注抑制人肺癌A549细胞移植瘤的作用。方法人肺癌A549细胞系经传代培养后,移植于40只祼大鼠建立肺癌裸大鼠模型。将荷瘤鼠均分为假手术组、吉西他滨组、塞来昔布组、联合组。假手术组动脉注入生理盐水0.2 mL。吉西他滨组、塞来昔布组分别经动脉灌注吉西他滨100 mg/kg及塞来昔布25 mg/kg。联合组灌注吉西他滨100 mg/kg+塞来昔布25 mg/kg。观察干预前后各组大鼠肿瘤体积的变化,计算荷瘤鼠的抑瘤率,流式细胞仪检测细胞的凋亡率,采用Western blot法检测各组Bcl-2以及Caspase-3表达情况。结果吉西他滨组、塞来昔布组和联合组的抑瘤率分别为54.18%,49.52%和88.59%;联合组移植瘤组织的Bcl-2表达量均低于其他3组( P均<0.05),Caspase-3表达量及凋亡指数均高于其他3组(P均<0.05)。结论塞来昔布与吉西他滨动脉灌注都能抑制肺癌裸大鼠移植瘤的生长,二者联合应用效果更好,诱导细胞凋亡是两者协同抗肿瘤作用的机制。
目的:研究塞來昔佈聯閤吉西他濱經動脈灌註抑製人肺癌A549細胞移植瘤的作用。方法人肺癌A549細胞繫經傳代培養後,移植于40隻祼大鼠建立肺癌裸大鼠模型。將荷瘤鼠均分為假手術組、吉西他濱組、塞來昔佈組、聯閤組。假手術組動脈註入生理鹽水0.2 mL。吉西他濱組、塞來昔佈組分彆經動脈灌註吉西他濱100 mg/kg及塞來昔佈25 mg/kg。聯閤組灌註吉西他濱100 mg/kg+塞來昔佈25 mg/kg。觀察榦預前後各組大鼠腫瘤體積的變化,計算荷瘤鼠的抑瘤率,流式細胞儀檢測細胞的凋亡率,採用Western blot法檢測各組Bcl-2以及Caspase-3錶達情況。結果吉西他濱組、塞來昔佈組和聯閤組的抑瘤率分彆為54.18%,49.52%和88.59%;聯閤組移植瘤組織的Bcl-2錶達量均低于其他3組( P均<0.05),Caspase-3錶達量及凋亡指數均高于其他3組(P均<0.05)。結論塞來昔佈與吉西他濱動脈灌註都能抑製肺癌裸大鼠移植瘤的生長,二者聯閤應用效果更好,誘導細胞凋亡是兩者協同抗腫瘤作用的機製。
목적:연구새래석포연합길서타빈경동맥관주억제인폐암A549세포이식류적작용。방법인폐암A549세포계경전대배양후,이식우40지관대서건립폐암라대서모형。장하류서균분위가수술조、길서타빈조、새래석포조、연합조。가수술조동맥주입생리염수0.2 mL。길서타빈조、새래석포조분별경동맥관주길서타빈100 mg/kg급새래석포25 mg/kg。연합조관주길서타빈100 mg/kg+새래석포25 mg/kg。관찰간예전후각조대서종류체적적변화,계산하류서적억류솔,류식세포의검측세포적조망솔,채용Western blot법검측각조Bcl-2이급Caspase-3표체정황。결과길서타빈조、새래석포조화연합조적억류솔분별위54.18%,49.52%화88.59%;연합조이식류조직적Bcl-2표체량균저우기타3조( P균<0.05),Caspase-3표체량급조망지수균고우기타3조(P균<0.05)。결론새래석포여길서타빈동맥관주도능억제폐암라대서이식류적생장,이자연합응용효과경호,유도세포조망시량자협동항종류작용적궤제。
Objective It is to compare the inhibiting effect on human lung adenocarcinoma who were treated with celecoxib combined with gemcitabine through arterial perfusion.Methods Human lung adenocarcinoma derived A549 cells were trans-planted into 40 BALB/c-nu mice to establish lung cancer model.The models were divided into 4 groups: animals in sham operation group ( A group) were treated with normal saline via arterial route, animals arterial perfusion with gemcitabine ( B group) were treated with gemcitabine 100 mg/kg, animals arterial perfusion with celecoxib( C group) were treated with cele-coxib 25 mg/kg, animals arterial perfusion with gemcitabine and celecoxib( D group) were treated with gemcitabine 100 mg/kg and celecoxib 25 mg/kg.Then dynamical change of tumor volume and tumor inhibiting rate were assessed , the inhibition rate was calculated,cell apoptosis was detected by flow cytometry,and Bcl-2 and Caspase 3 expressions were investigated using western blot.Results The inhibition rate of A group B group and C group were 54.18%,49.52%and 88.59%.Expression of Bcl-2 in lung adenocarcinoma of D group was lower than other three group(P<0.05),while expression of Caspase-3 was up regulated.Apoptotic index of lung adenocarcinoma of D group were higher than other three groups,Transplanted tumors in arterial and intravenous chemotherapy group(P<0.05).Conclusion Human lung adenocarcinoma can be inhibited by cele-coxib combined with gemcitabine through arterial perfusion, synergism anti-tumor activity was happened through inducing the apoptosis of tumor cell.